In Silico Methods for Predicting Drug Toxicity
| Autor Corporativo: | |
|---|---|
| Otros Autores: | |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
New York, NY :
Springer New York : Imprint: Humana,
2016.
|
| Edición: | 1st ed. 2016. |
| Colección: | Methods in Molecular Biology,
1425 |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1007/978-1-4939-3609-0 |
Tabla de Contenidos:
- QSAR Methods
- In Silico 3D-Modelling of Binding Activities
- Modeling Pharmacokinetics
- Modeling ADMET
- In Silico Prediction of Chemically-Induced Mutagenicity: How to Use QSAR Models and Interpret Their Results
- In Silico Methods for Carcinogenicity Assessment
- VirtualToxLab: Exploring the Toxic Potential of Rejuvenating Substances Found in Traditional Medicines
- In Silico Model for Developmental Toxicity: How to Use QSAR Models and Interpret Their Results
- In Silico Models for Repeated Dose Toxicity (RDT): Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for Drugs
- In Silico Models for Acute Systemic Toxicity
- In Silico Models for Hepatotoxicity
- In Silico Models for Ecotoxicity of Pharmaceuticals
- Use of Read-Across Tools
- Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity
- A Systems Biology Approach for Identifying Hepatotoxicant Groups Based on Similarity in Mechanisms of Action and Chemical Structure
- In Silico Study of In Vitro GPCR Assays by QSAR Modeling
- Taking Advantage of Databases
- QSAR Models at the United States FDA/NCTR
- A Round Trip from Medicinal Chemistry to Predictive Toxicology
- The Use of In Silico Models Within a Large Pharmaceutical Company
- The Consultancy Activity on In Silico Models for Genotoxic Prediction of Pharmaceutical Impurities.